The role of the Biostatistics Core is to support the investigators of the SPORE in Prostate Cancer in their research efforts, including laboratory experiments and the design and analysis of clinical trials. In preclinical studies, core members will assist in the formulation of the experimental design and in the analysis and interpretation of the data at the conclusion of the study. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator. Based on this review, a statistical section for the protocol will be provided, outlining major scientific objectives, population to be studied, primary and secondary endpoints, experimental design, a randomization procedure if necessary, analysis plans, and a targeted sample size justified in probabilistic terms. At the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol.
The specific aims of the Biostatistics Core are to:
Aim 1 : Contribute to the design and analysis of laboratory-based prostate cancer research Aim 2: Contribute to the design and analysis of clinical studies in prostate cancer Aim 3: Develop statistical methodology that will assist in the advancement of prostate cancer research
The Biostatistics Core assists the research efforts of the MSKCC SPORE in Prostate Cancer investigators, contributing to the design and analysis of clinical and laboratory research and the development of valid conclusions. The core provides statistical analysis and consultancy as well as ongoing quality assurance. The core has also established a data quality working group to improve the quality of SPORE data.
|Kinsella, Netty; Stattin, Pär; Cahill, Declan et al. (2018) Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. Eur Urol 74:261-280|
|Li, Weiqiang; Middha, Mridu; Bicak, Mesude et al. (2018) Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur Urol 74:710-719|
|Aras, Omer; Pearce, Gillian; Watkins, Adam J et al. (2018) An in-vivo pilot study into the effects of FDG-mNP in cancer in mice. PLoS One 13:e0202482|
|Sjoberg, Daniel D; Vickers, Andrew J; Assel, Melissa et al. (2018) Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Eur Urol 73:941-948|
|Vickers, Andrew J; Young-Afat, Danny A; Ehdaie, Behfar et al. (2018) Just-in-time consent: The ethical case for an alternative to traditional informed consent in randomized trials comparing an experimental intervention with usual care. Clin Trials 15:3-8|
|Assel, Melissa; Dahlin, Anders; Ulmert, David et al. (2018) Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 73:961-967|
|Han, SoHyun; Stoyanova, Radka; Lee, Hansol et al. (2018) Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity. Magn Reson Med 79:1736-1744|
|Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245|
|Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97|
|Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:|
Showing the most recent 10 out of 505 publications